GE Healthcare teams with CBMG to develop CAR-T and stem cell production tech

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Stem cell

GE Healthcare has agreed to help Cellular Biomedicine Group (CBMG) develop CAR-T and stem cell production technologies to support its aim of making 10,000 cancer cell therapies a year. 

Research will be carried out at CBMG’s facility at the Zhangjiang High-Tech Park in Shanghai, with the aim being to develop a cell production and preparation system.

A GE Healthcare spokeswoman told us "the project will be focused to integrate GE technologies Sefia, Sepax 2, Xuri, SmartMax, and consumables, as well as our newly announced Asymptote VIA Freeze product line into CBMG Car-T and stem cell manufacturing process​."  

She added that: "The agreement spans two years, with option to extend.​"

The firms also plan to install CAR-T and stem cell manufacturing capacity at CBMG’s plants in Wuxi and Beijing.

CBMG has a total 70,000 square feet of manufacturing space at its sites. The firm claims that, if operating at full production volumes, its facilities could “support the treatment of up to 10,000 cancer patients and 10,000 knee osteoarthritis patients per year​.”

GE Healthcare has co-developed a number of biopharma facilities in China with companies including Pfizer​, JHL​ and BeiGene​. However, as the spokeswoman confirmed "this is the first cell therapy project in this scope that we publicly announce for collaboration in China​."

Asymptote acquisition

In related news, GE announced it has acquired Asymptote Limited, a UK-based cryochain technology supplier for sensitive cellular therapies. 

The deal - terms of which were not provided - "fills a critical gap in GE Healthcare’s end-to-end ecosystem of products and services for cell therapy production​" according to the firm.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more